Crowdonomics
WatchlistPortfolio
All companies
Lexington Biomedical, Inc. logo

Lexington Biomedical, Inc.

Operating

Biotech · Cambridge, MA

Visit website
Post-money valuation ⓘ
$12.3M
As of Apr 2025 · from Reg CF Offering (2025) · pre-money + amount raised, not a traded price
Total raised
$0
Across 1 round since 2025
Latest share price
$1.23
Reg CF Offering (2025) offering price

Financials

FY2022–FY2023 · from SEC filings · hover any figure for its source
$0
−$287K
2022
$0
−$304K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022 reviewed
FY2023 reviewed
Income statement
Revenue
$0
$0
Cost of goods sold
$280,165
$304,063
Net income
-$286,980
-$304,063
Taxes paid
$0
$0
Balance sheet
Cash
$58,458
$18,710
Accounts receivable
$0
$0
Total assets
$126,518
$57,189
Short-term debt
$298,985
$386,794
Long-term debt
$1,000,361
$1,148,180
Total liabilities
$1,299,346
$1,534,974
Other
Headcount
—
2

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$12.3M
pre-money
Reg CF · Series A Preferred · Mar 2025

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Reg CF · Series A Preferred Stock · Mar 2025Closedvia StartEngine
Raised $0 / $1.2MPost-money $12.3M

Team

5 people
Jean Manuel SobarzoFounder
Founder, CEO, and Chairman of the Board
Robert FrankFounder
Co-Founder and Chief Cardiology Officer
David T. Martin
Board Member and Chief Cardiology Advisor
Philippe Pierre Sauvage
Chief Strategy Advisor Post Funding, Board Member
W. Scott Hoge
Board Member, Director of Science and Chief Technology Officer

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not obligated

never closed a Reg CF raise

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-UApr 21, 20250001665160-25-000729
    EDGAR
  • Form CMar 17, 20250001665160-25-000423
    EDGAR
Source: SEC EDGARCIK 0002057514DEShare price $1.23Last synced Aug 17, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.